RxDoctor Payments Data

Gary McDonald, MD

Internal Medicine · Nashville, TNNPI 1013957976

Payments from drug & device makers

$13,123in general payments, 2019–2025

Across 760 payments — averaging $17.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$2K
  • AstraZeneca$1K
  • AbbVie$965
  • Pfizer$942
  • Amgen$918
  • Novartis$816
  • plus $6K from 33 others

What the payments were for

  • Food & beverage$13,03599%
  • Education$881%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$13,123 in reported general payments places this provider in the 95th percentile of 2,216 internal medicine providers in Tennessee.

See all internal medicine providers in Tennessee

Medicare billing

Part B allowed, 2024
$30,774
Medicare patients
187
Services billed
8,006

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide139$158,116
EliquisApixaban80$76,623
MounjaroTirzepatide76$73,922
FarxigaDapagliflozin Propanediol58$49,597
JardianceEmpagliflozin60$44,913
RybelsusSemaglutide42$40,697
TrulicityDulaglutide29$39,444
XareltoRivaroxaban28$23,526
Trelegy ElliptaFluticasone/Umeclidin/Vilanter25$18,472
CreonLipase/Protease/Amylase12$14,406
JanuviaSitagliptin Phosphate19$10,555
Breztri AerosphereBudesonide/Glycopyr/Formoterol13$8,060
EntrestoSacubitril/Valsartan11$7,876
Breo ElliptaFluticasone/Vilanterol18$7,844
Ezetimibe180$7,682

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$2,415$198,813181 claims
Lilly USA, LLCMounjaro, Trulicity$710$113,366105 claims
PfizerEliquis, Paxlovid$942$79,314111 claims
AstraZenecaFarxiga, Breztri Aerosphere$1,281$57,65771 claims
Boehringer IngelheimJardiance$609$44,91360 claims
GSKTrelegy Ellipta, Breo Ellipta$673$26,31743 claims
Johnson & JohnsonXarelto$249$23,52628 claims
AbbVieCreon$965$14,40612 claims
MerckJanuvia$226$10,55519 claims
NovartisEntresto$816$7,87611 claims
Sanofi-aventis U.S. LLCPlavix$195$3,37712 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$31$1,662193 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,216 internal medicine providers in Tennessee.

Other internal medicine in Nashville

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →